Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 2Spondylitis, Ankylosing 1Signs and Symptoms 1Psoriasis 1Nutrition Disorders 1Lymphoma 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Inflammatory Bowel Diseases 1Glioma 1Gastroparesis 1Feeding and Eating Disorders 1Esophageal Neoplasms 1Epilepsy 1Dumping Syndrome 1Diarrhea 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Sirolimus 4Everolimus 3Anticonvulsants 2ziprasidone 1perampanel 1enzalutamide 1clevidipine 1brivaracetam 1Zolpidem 1Warfarin 1Vigabatrin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Tobramycin 1Therapeutic Touch 1Temozolomide 1Surgical Procedures, Operative 1Sulfasalazine 1Spironolactone 1Sevoflurane 1Sevelamer 1Saline Solution 1Rocuronium 1Registries 1Radiotherapy 1Propofol 1Piperacillin, Tazobactam Drug Combination 1Pentobarbital 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Epilepsy × Sulfasalazine × Clear all
NCT05664464 2024-05-10

GLUGLIO

University of Zurich

Phase 1/2 Recruiting
120 enrolled
CNS

Epilepsy, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡